• Moderate to severe plaque psoriasis.
• Active psoriatic arthritis (with or without methotrexate).
• Active ankylosing spondylitis.

Contraindicated in:

• Hypersensitivity.

Use Cautiously in:

• Chronic infection/history recurrent infection (including tuberculosis)
• Inflammatory bowel disease (exacerbation may occur)
• OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk; Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
• Pedi: Safety and effectiveness not established in children.

GI: diarrhea, inflammatory bowel disease.
Misc: (INCLUDING ANAPHYLAXIS) HYPERSENSITIVITY REACTIONS , INFECTION.

Drug-Drug:

• ↑risk of adverse reactions with live vaccines; do not administer concurrently.
• Administration of non-live vaccines may not elicit antibody response sufficient to produce protection.
• May affect activity of CYP450 enzymes and may alter the effectiveness/toxicity of CYP450 substrate, including warfarin and cyclosporine; close monitoring is recommended and necessary dose modifications undertaken.

• Lyophilized powder for injection: 150 mg/vial;
• Solution for injection (caps contain latex) (prefilled syringes or Sensoready pen): 150 mg/mL;

Plaque Psoriasis

• SC (Adults): 300 mg once weekly for 5 wk, then 300 mg every 4 wk; for selected patients, a dose of 150 mg may be sufficient.

Psoriatic Arthritis

• SC (Adults): Initiate therapy with or without a loading dose. With loading dose — 150 mg once weekly for 5 wk, then 150 mg every 4 wk; if patient continues to have symptoms, may ↑ dose to 300 mg; Without loading dose — 150 mg every 4 wk; if patient continues to have symptoms, may ↑ dose to 300 mg.

Ankylosing Spondylitis

• SC (Adults): Initiate therapy with or without a loading dose. With loading dose — 150 mg once weekly for 5 wk, then 150 mg every 4 wk; Without loading dose — 150 mg every 4 wk.

Cosentyx

• A monoclonal antibody that acts as an antagonist of interleukin (IL)–17A by selectively binding to it and preventing its interaction with the IL–17 receptor. Antagonism prevents the production of inflammatory cytokines and chemokines.

• Decreased plaque formation and spread.
• Decreased progression of and decreased structural damage associated with psoriatic arthritis.
• Decreased signs and symptoms in ankylosing spondylitis.

Therapeutic Classification: antipsoriatics

Pharmacologic Classification: interleukin antagonists

Absorption: Well absorbed following subcutaneous administration.

Distribution: Levels in interstitial fluid of skin (lesional and non-lesional) are 27–40% those of serum.

Metabolism/Excretion: Catabolized into small peptides and amino acids.

Half-life: 22–31 days.

(blood level)

• Instruct patient on the correct technique for administering secukinumab. Review Medication Guide, preparation of dose, administration sites and technique, and disposal of equipment into a puncture-resistant container. Advise patient to review Medication Guide with each Rx in case of changes.
• Caution patient to notify health care professional immediately if signs of infection, severe rash, swollen face, or difficulty breathing occur while taking secukinumab.
• Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
• Advise patient to avoid live vaccines during therapy.
• Instruct patient to notify health care professional of medication regimen prior to treatment or surgery.
• Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
• Sensoready Pen: Clean area for injection with alcohol swab. Hold pen with cap pointing up. Check solution through window; if discolored, cloudy, or contains flakes, discard solution. Remove cap. Place pen, with window visible, against skin at a 90° angle and press button until 2 clicks are heard. First click indicates injection started; 2nd click indicates injection is almost complete. Hold pen in place until all solution is injected (10 seconds) and green marker is visible in window and has filled window. Remove needle and press with a gauze pad or cotton ball for 10 seconds. Do not rub injection site. Dispose of pen into a puncture-resistant container.

sek-ue-KIN-ue-mab